How AOC Will Change The World

The Next Great Medical Technology Has Arrived And Trillions Are At Stake

This is Porter’s Daily Journal, a free e-letter from Porter & Co. that provides unfiltered insights on markets, the economy, and life to help readers become better investors. It includes weekday editions and two weekend editions… and is free to all subscribers.

Table of Contents

• The Next Great Medical Technology Has Arrived And …

• This Will Be The Biggest Story Of Our Careers

• Understand The Platform – Understand The Opportuni …

• The Nobel Prize-Winning Discovery

• White House Insider Buck Sexton:

• “Trump’s Next Move Will Shock The World”

• Three Things To Know Before We Go…

• And One More Thing… Watching Carvana’s Earnings

• Mailbag

Yesterday one of the world’s leading biotech companies spent $11 billion to buy a single “bridge.”

It’s called AOC – but it’s not a bartender turned socialist rabble-rouser.

And it’s not some new form of artificial intelligence (“AI”).

AOC – antibody-oligonucleotide conjugates – is the key technological bridge that will expand RNA interference treatments beyond the liver.

You probably haven’t heard about any of this stuff. But you will. Novartis (NVS) thinks AOC is worth $11 billion. And, in time, we expect this “bridge” will be worth hundreds of billions.

Or even trillions.

If you will take the time today to read, to fully consider, and to act on the information below, I have no doubt it will change your investing life, forever.

In today’s Daily Journal, I am going to tell you everything you need to know to make millions of dollars as investors over the next decade.

That isn’t an exaggeration. And it’s not hypothetical. In fact, we are already doing this for people who trusted us enough to buy and read Erez Kalir’s Tech Frontiers.

Subscribers have already seen a set of recommendations that’s earned well more than 50% annual returns since inception. That’s not just one recommendation: that’s the total annualized return of all of our Tech Frontiers recommendations.

There’s absolutely no reason you can’t be part of that.

As yesterday’s big Novartis purchase demonstrates, this new foundational technology – siRNA, which I’ll describe in more detail below – is only now making its way into Big Pharma’s pipelines.

There is still plenty of time to get in before any of the big money is made.